@article{5dcfa7a2b38a42a9a1727ec37b940d60,
title = "Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients",
abstract = "A fraction of patients with COVID-19 develops severe disease requiring hospitalization, while the majority, including high-risk individuals, experience mild symptoms. Severe disease has been associated with higher levels of antibodies and inflammatory cytokines but often among patients with diverse demographics and comorbidity status. This study evaluated hospitalized vs. ambulatory patients with COVID-19 with demographic risk factors for severe COVID-19: median age of 63, >80% male, and >85% black and/or Hispanic. Sera were collected four to 243 days after symptom onset and evaluated for binding and functional antibodies as well as 48 cytokines and chemokines. SARS-CoV-2-specific antibody levels and functions were similar in ambulatory and hospitalized patients. However, a strong correlation between anti-S2 antibody levels and the other antibody parameters, along with higher IL-27 levels, was observed in hospitalized but not ambulatory cases. These data indicate that antibodies against the relatively conserved S2 spike subunit and immunoregulatory cytokines such as IL-27 are potential immune determinants of COVID-19.",
keywords = "Health sciences, Immune response, Immunology, Population",
author = "J{\'e}romine Klingler and Lambert, {Gregory S.} and Bandres, {Juan C.} and Rozita Emami-Gorizi and Arthur N{\'a}das and Oguntuyo, {Kasopefoluwa Y.} and Fatima Amanat and Berm{\'u}dez-Gonz{\'a}lez, {Maria C.} and Charles Gleason and Giulio Kleiner and Viviana Simon and Benhur Lee and Susan Zolla-Pazner and Chitra Upadhyay and Hioe, {Catarina E.}",
note = "Funding Information: We thank Dr. Florian Krammer for providing spike and RBD antigens, and all the study participants for their contribution to the research. We would like to thank the expertise and assistance of Dr. Christopher Bare and the Dean{\textquoteright}s Flow Cytometry CORE at Mount Sinai. We are grateful the entire Personalized Virology Initiative (PVI) Team— specially L.C.F. Mulder, E. Kojic, G. Osorio, M. Ng, D. Altman, F. Rahman, M. Saksena, K. Srivastava, K. Beach, K. Russo, L. Sominsky, E. Ferreri, R. Chernet, L. Eaker, A. Salimbangon, and W. Mendez—for enrolling study participants with COVID-19 as well as processing and banking their biospecimen. This work was supported in part by the Department of Medicine of the Icahn School of Medicine at Mount Sinai (to S.Z-P., C.E.H.); the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai (to B.L.), the Department of Veterans Affairs [Merit Review Grant I01BX005794 ] (to C.E.H.) and [Research Career Scientist Award 1IK6BX004607 ] (to C.E.H.); the National Institutes of Health [grant AI139290 ] to C.E.H., [grants R01 AI123449 , R21 AI1498033 ] to B.L., [grant R01 AI140909 ] to C.U. The PVI received institutional funding as well as anonymous philanthropic donations. The study sponsors had no involvement in study design, data collection, analysis, and interpretation, manuscript writing, and decision to submit the paper for publication. Funding Information: We thank Dr. Florian Krammer for providing spike and RBD antigens, and all the study participants for their contribution to the research. We would like to thank the expertise and assistance of Dr. Christopher Bare and the Dean's Flow Cytometry CORE at Mount Sinai. We are grateful the entire Personalized Virology Initiative (PVI) Team— specially L.C.F. Mulder, E. Kojic, G. Osorio, M. Ng, D. Altman, F. Rahman, M. Saksena, K. Srivastava, K. Beach, K. Russo, L. Sominsky, E. Ferreri, R. Chernet, L. Eaker, A. Salimbangon, and W. Mendez—for enrolling study participants with COVID-19 as well as processing and banking their biospecimen. This work was supported in part by the Department of Medicine of the Icahn School of Medicine at Mount Sinai (to S.Z-P. C.E.H.); the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai (to B.L.), the Department of Veterans Affairs [Merit Review Grant I01BX005794] (to C.E.H.) and [Research Career Scientist Award 1IK6BX004607] (to C.E.H.); the National Institutes of Health [grant AI139290] to C.E.H. [grants R01 AI123449, R21 AI1498033] to B.L. [grant R01 AI140909] to C.U. The PVI received institutional funding as well as anonymous philanthropic donations. The study sponsors had no involvement in study design, data collection, analysis, and interpretation, manuscript writing, and decision to submit the paper for publication. J.K. S.Z-P. C.U. and C.E.H. wrote and edited the manuscript. J.K. C.E.H. and S.Z-P. designed the experiments. J.K. and G.S.L. performed the experiments and collected the data. J.K. G.S.L. A.N. C.U. and C.E.H. analyzed the data. K.Y.O. F.A. and B.L. provided protocols, antigens, cells, and pseudovirus stocks. V.S. G.K. M.C.B. and C.G. provided banked human samples and metadata, J.C.B. and R.E-G. obtained specimens and clinical data. All authors read and approved the final manuscript. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays (U.S. Provisional Application Number 63/051,858, which list Viviana Simon as co-inventor). Publisher Copyright: {\textcopyright} 2022 The Authors",
year = "2022",
month = dec,
day = "22",
doi = "10.1016/j.isci.2022.105608",
language = "English",
volume = "25",
journal = "iScience",
issn = "2589-0042",
publisher = "Elsevier Inc.",
number = "12",
}